aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
aTyr Pharma shares plunged more than 80% after its Phase III trial in pulmonary sarcoidosis failed to meet its primary…
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…
Alfasigma plans to engage with regulators to seek approval for Jyseleca (filgotinib) in active axial spondyloarthritis (axSpA) following a successful…
After two weeks in the regulatory wringer, Sarepta Therapeutics has been given clearance to continue shipments of its Duchenne muscular…
Sarepta has suffered another regulatory setback after the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP)…
Danish weight-loss giant Novo Nordisk has lost a US patent to generics manufacturer Viatris. A federal district court in Delaware…
The UK Government has passed legislation to decentralise the manufacture of personalised medicines, allowing them to be prepared in facilities…
Sarepta Therapeutics has yielded to the US Food and Drug Administration (FDA), agreeing to suspend shipments of Elevidys (delandistrogene moxeparvovec)…